Haemophilus Infections: all 176 studies

Page 1 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Study of BK1803 in Healthy InfantsRecruitingNCT07793513Phase 3
• Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined VaccineRecruitingNCT07203755Phase 1
• Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgeNot yet recruitingNCT06618196Phase 2
• Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old InfantsRecruitingNCT06605755Not applicable
• A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy AdultsNot yet recruitingNCT05952596Phase 1
• Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)CompletedNCT04978818Phase 4Results posted
• A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and ToddlersCompletedNCT04535037Phase 4Results posted
• Confirmatory Study of BK1310 in Healthy InfantsCompletedNCT03891758Phase 3Results posted
• Safety and Efficacy of BK1310 Intramuscular Injection in Healthy InfantsCompletedNCT03188692Phase 3Results posted
• Phase 3 Study of BK1310 in Healthy InfantsCompletedNCT02992925Phase 3Results posted
• A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in RussiaCompletedNCT02858440Phase 3Results posted
• Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02853929Phase 4Results posted
• A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy InfantsCompletedNCT02447432Phase 3Results posted
• Exploratory Clinical Study of MT-2301CompletedNCT02140047Phase 2Results posted
• Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese ChildrenCompletedNCT02139228Phase 3Results posted
• Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsCompletedNCT02096263Phase 3Results posted
• Phase III Study of Intramuscular TAK-816 in Healthy InfantsCompletedNCT02074345Phase 3Results posted
• Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of AgeCompletedNCT01978093Phase 3Results posted
• Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeCompletedNCT01659996Phase 4Results posted
• Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy InfantsCompletedNCT01616459Phase 2Results posted
• Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese ToddlersCompletedNCT01577732Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)CompletedNCT01480258Phase 3Results posted
• Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01453998Phase 2Results posted
• Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) VaccineCompletedNCT01449812Phase 3Results posted
• Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BCompletedNCT01362517Phase 3Results posted
• Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™CompletedNCT01358825Phase 4Results posted
• Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood VaccinationCompletedNCT01357720Phase 4Results posted
• Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccineCompletedNCT01353703Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)CompletedNCT01341639Phase 3Results posted
• A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)CompletedNCT01340937Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)CompletedNCT01337167Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccineCompletedNCT01309646Phase 3Results posted
• Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & InfantsCompletedNCT01262872Phase 2Results posted
• Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)CompletedNCT01248884Phase 2Results posted
• Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy InfantsCompletedNCT01204658Phase 2Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedNCT01171989Phase 2Results posted
• Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster DoseCompletedNCT01119625Phase 3Results posted
• Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy ToddlersCompletedNCT01106092Phase 2Results posted
• Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsCompletedNCT01090453Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ VaccineCompletedNCT01086423Phase 3Results posted
• Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy InfantsCompletedNCT01000974Phase 3Results posted
• Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First VaccinationCompletedNCT00985751Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeCompletedNCT00970307Phase 2Results posted
• Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)CompletedNCT00964028Phase 3Results posted
• Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™CompletedNCT00907777Phase 3Results posted
• Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib VaccinesCompletedNCT00891176Phase 3Results posted
• Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.TerminatedNCT00871741Phase 2Results posted
• Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in InfantsCompletedNCT00871338Phase 2Results posted
• Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive DiseaseCompletedNCT00861380Phase 3Results posted
• Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850ACompletedNCT00839254Phase 3Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian InfantsCompletedNCT00831753Phase 3Results posted
• Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean InfantsCompletedNCT00831311Phase 2Results posted
• Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young AdultsCompletedNCT00814489Phase 1Results posted
• Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™CompletedNCT00802867Phase 4Results posted
• Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™CompletedNCT00772928Phase 3Results posted
• Retrospective Survey of Safety of Fourth Dose Pentacel® in ChildrenCompletedNCT00772369Results posted
• Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in InfantsCompletedNCT00753649Phase 4Results posted
• Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™CompletedNCT00654901Phase 3Results posted
• Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib VaccineCompletedNCT00627458Phase 2Results posted
• Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate VaccineCompletedNCT00624819Phase 3Results posted
• Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired PneumoniaCompletedNCT00621504Phase 3Results posted
• Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm InfantsCompletedNCT00586612Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™CompletedNCT00534833Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino InfantsCompletedNCT00514709Phase 3Results posted
• Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired PneumoniaCompletedNCT00509106Phase 3Results posted
• Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3Results posted
• Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/HibCompletedNCT00473668Phase 3Results posted
• Study of Long-term Antibody Persistence After a Booster Dose of Menitorix VaccineCompletedNCT00454987Phase 4Results posted
• Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)CompletedNCT00441012Phase 3Results posted
• Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 3Results posted
• Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3Results posted
• Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai InfantsCompletedNCT00401531Phase 3Results posted
• A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3Results posted
• Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPVCompletedNCT00362336Phase 3Results posted
• Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIBCompletedNCT00359983Phase 3Results posted
• Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsCompletedNCT00348881Phase 3Results posted
• Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.CompletedNCT00345683Phase 3Results posted
• Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of AgeCompletedNCT00345579Phase 3Results posted
• Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio VaccineCompletedNCT00343889Phase 3Results posted
• Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.CompletedNCT00326118Phase 3Results posted
• Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy InfantsCompletedNCT00325156Phase 4Results posted
• Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B VaccineCompletedNCT00325143Phase 3Results posted
• Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenCCompletedNCT00322335Phase 3Results posted
• Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed SubjectsCompletedNCT00317109Phase 3Results posted
• Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months ScheduleCompletedNCT00315055Phase 3Results posted
• Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.CompletedNCT00313911Phase 3Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsCompletedNCT00303316Phase 3Results posted
• Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 StudyCompletedNCT00291343Phase 3Results posted
• Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccineCompletedNCT00289783Phase 3Results posted
• Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in ChildrenCompletedNCT00228917Phase 3Results posted
• Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in InfantsCompletedNCT00169442Phase 3Results posted
• Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30mCompletedNCT00136604Phase 3Results posted
• Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate VaccinesCompletedNCT00134719Phase 2Results posted
• Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal VaccineCompletedNCT00129129Phase 2Results posted
• 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of AgeCompletedNCT00129116Phase 2Results posted
• Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) VaccineCompletedNCT00127855Phase 2Results posted
• Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate VaccineActive, not recruitingNCT07743008Phase 2
• Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care ManagementCompletedNCT07322549
• A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesActive, not recruitingNCT06947499Phase 2/3
• Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate VaccineActive, not recruitingNCT06621654Phase 1

← Haemophilus Infections overview